Hospital Access, Reimbursement Slowing Effient Uptake, Execs Say
Executive Summary
It wasn't long ago that Eli Lilly/Daiichi Sankyo's blood thinner Effient (prasugrel) was still considered an obvious blockbuster, kind of like a James Cameron movie. But now, six months post launch, Effient looks more like an art house film that might play well with a certain audience
You may also be interested in...
AstraZeneca's Brilinta: Can Advisory Committee Help Build Momentum?
Antiplatelet ticagrelor will likely confront the "North American anomaly" during its July 28 review by FDA's cardio-renal panel.
A Return Of The Blockbuster, But Can 2009 Launches Live Up To Potential?
The blockbuster drug tried to claw its way back from the brink in 2009, as drug makers launched several novel drugs and biologics in multi-billion dollar therapeutic categories. While several new drugs offer blockbuster potential, they raise two questions: will they live up to their promise, and if so, how long will it take
A Return Of The Blockbuster, But Can 2009 Launches Live Up To Potential?
The blockbuster drug tried to claw its way back from the brink in 2009, as drug makers launched several novel drugs and biologics in multi-billion dollar therapeutic categories. While several new drugs offer blockbuster potential, they raise two questions: will they live up to their promise, and if so, how long will it take